Proton pump inhibitors therapy and cyp2c19 gene variability in
Czech patients with gastroesophageal reflux disease: pilot
study

a 2017

Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study

BOŘILOVÁ LINHARTOVÁ, Petra, Ladislav BARTOŠ, Ladislava BARTOŠOVÁ, Adam KŘENEK, Jiří DOLINA et. al.

Základní údaje

Originální název

Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study

Autoři

BOŘILOVÁ LINHARTOVÁ, Petra (203 Česká republika, domácí), Ladislav BARTOŠ (203 Česká republika, domácí), Ladislava BARTOŠOVÁ (203 Česká republika, domácí), Adam KŘENEK (203 Česká republika), Jiří DOLINA (203 Česká republika), Filip MAREK (203 Česká republika), Zdeněk KALA (203 Česká republika) a Lydie IZAKOVIČOVÁ HOLLÁ (203 Česká republika, domácí)

Vydání

67. Česko-Slovenské Farmakologické dni, 2017

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/17:00095039

Organizační jednotka

Lékařská fakulta

ISSN

Klíčová slova anglicky

Proton pump inhibitors

Štítky

EL OK

Změněno: 14. 12. 2017 13:38, Soňa Böhmová

Anotace

V originále

Proton pump inhibitors (PPIs) are a class of drugs used as the first-line therapy to treat gastroesophageal reflux disease (GERD). PPIs are metabolized mainly by cytochrome P450 2C19 (CYP2C19). The aim of the pilot study was to map the use of these drugs in Czech patients with various degrees of GERD and to analyze their individual variability in the gene encoding the CYP2C19. A total of 280 subjects (mean age±standard deviation: 46.23±13.11 years) were enrolled in the study: 95 patients with non-erosive reflux disease (NERD), 124 with reflux esophagitis (RE) and 61 with Barrett's esophagus (BE) or esophageal adenocarcinoma (EAC). The diagnosis was determined on the basis of clinical symptoms such as heartburn (pyrosis) and/or acid regurgitation; objectified with 24-h pH-metry, esophagogastroduodenoscopy and manometry. The determination of genotypes of two polymorphisms in the CYP2C19 gene (*17 rs12248560 and *2 rs4244285) was based on the principle of real-time polymerase chain reaction with TaqMan assays. Almost 90% patients with GERD took one or more PPIs (omeprazole, pantoprazole and/or lansoprazole). In addition, 37% patients took some prokinetics and 16.4% patients had polypragmasy. The results of haplogenotype analyses of the CYP2C19 gene classified 36.8% patients into a group of extensive metabolizers (*1*1/*1*1) or even ultrarapid metabolizers 37.2% (*1*1/*1*17 and *1*1/*17*17); only smaller numbers of patients were intermediate or poor metabolizers (17.1% or 1.4%, respectively). We concluded that the most common loss-of-function CYP2C19*2 and gain-of-function CYP2C19*17 variants should be examined in patients with GERD before PPI pharmacotherapy is prescribed. Selection of adequate drugs and their proper dosing may contribute to improve patients’s life quality and prevent the progression to more severe GERD conditions such as BE and EAC.

Návaznosti

GB14-37368G, projekt VaV

Název: Centrum orofaciálního vývoje a regenerace

Investor: Grantová agentura ČR, Centrum orofaciálního vývoje a regenerace

MUNI/A/0948/2016, interní kód MU

Název: Nemoci dutiny ústní – etiopatogeneze, klinické projevy, diagnostika a léčba

Investor: Masarykova univerzita, Nemoci dutiny ústní – etiopatogeneze, klinické projevy, diagnostika a léčba, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

ROZV/25/LF/2017, interní kód MU

Název: LF - Příspěvek na IP 2017

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, LF - Příspěvek na IP 2017, Interní rozvojové projekty

Citovat

BOŘILOVÁ LINHARTOVÁ, Petra, Ladislav BARTOŠ, Ladislava BARTOŠOVÁ, Adam KŘENEK, Jiří DOLINA, Filip MAREK, Zdeněk KALA a Lydie IZAKOVIČOVÁ HOLLÁ. Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study. In 67. Česko-Slovenské Farmakologické dni. 2017. ISSN 1337-6853.

@proceedings{1391617,
   author = {Bořilová Linhartová, Petra and Bartoš, Ladislav and Bartošová, Ladislava and Křenek, Adam and Dolina, Jiří and Marek, Filip and Kala, Zdeněk and Izakovičová Hollá, Lydie},
   booktitle = {67. Česko-Slovenské Farmakologické dni},
   keywords = {Proton pump inhibitors},
   language = {eng},
   title = {Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study},
   year = {2017}
}

TY  - CONF
ID  - 1391617
AU  - Bořilová Linhartová, Petra - Bartoš, Ladislav - Bartošová, Ladislava - Křenek, Adam - Dolina, Jiří - Marek, Filip - Kala, Zdeněk - Izakovičová Hollá, Lydie
PY  - 2017
TI  - Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study
KW  - Proton pump inhibitors
N2  - Proton pump inhibitors (PPIs) are a class of drugs used as the first-line therapy to treat gastroesophageal reflux disease (GERD). PPIs are metabolized mainly by cytochrome P450 2C19 (CYP2C19). The aim of the pilot study was to map the use of these drugs in Czech patients with various degrees of GERD and to analyze their individual variability in the gene encoding the CYP2C19. A total of 280 subjects (mean age±standard deviation: 46.23±13.11 years) were enrolled in the study: 95 patients with non-erosive reflux disease (NERD), 124 with reflux esophagitis (RE) and 61 with Barrett's esophagus (BE) or esophageal adenocarcinoma (EAC). The diagnosis was determined on the basis of clinical symptoms such as heartburn (pyrosis) and/or acid regurgitation; objectified with 24-h pH-metry, esophagogastroduodenoscopy and manometry. The determination of genotypes of two polymorphisms in the CYP2C19 gene (*17 rs12248560 and *2 rs4244285) was based on the principle of real-time polymerase chain reaction with TaqMan assays. Almost 90% patients with GERD took one or more PPIs (omeprazole, pantoprazole and/or lansoprazole). In addition, 37% patients took some prokinetics and 16.4% patients had polypragmasy. The results of haplogenotype analyses of the CYP2C19 gene classified 36.8% patients into a group of extensive metabolizers (*1*1/*1*1) or even ultrarapid metabolizers 37.2% (*1*1/*1*17 and *1*1/*17*17); only smaller numbers of patients were intermediate or poor metabolizers (17.1% or 1.4%, respectively). We concluded that the most common loss-of-function CYP2C19*2 and gain-of-function CYP2C19*17 variants should be examined in patients with GERD before PPI pharmacotherapy is prescribed. Selection of adequate drugs and their proper dosing may contribute to improve patients’s life quality and prevent the progression to more severe GERD conditions such as BE and EAC.
ER  -

BOŘILOVÁ LINHARTOVÁ, Petra, Ladislav BARTOŠ, Ladislava BARTOŠOVÁ, Adam KŘENEK, Jiří DOLINA, Filip MAREK, Zdeněk KALA a Lydie IZAKOVIČOVÁ HOLLÁ. Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study. In \textit{67. Česko-Slovenské Farmakologické dni}. 2017. ISSN~1337-6853.

Podrobný výpis o publikaci